Norwood, MA (PRWEB) April 15, 2013
BioPharm Insight Global Editor Kimberly Ha will moderate a panel discussion on “Emerging Licensing Opportunities” at the 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China, May 20-21 in Boston, Mass.
BioPharm Insight offers the global biopharmaceutical community a unique combination of business intelligence, market analytics, key industry contacts, and award-winning independent investigative journalism.
The panel of China and Asia market experts will discuss strategies to maximize the value of drug candidates starting in the pre-clinical development stage. Presenters will explore strategies small to mid-size drug developers should take to position themselves for out-licensing, and discuss emerging opportunities for licensing in China/Asia. Panelists will cover alternative investment approaches and new ways to structure the deals. They also will share case studies and best practices to align goals with deal opportunities, navigate negotiation challenges, and establish clear protocols to manage relationships and create lucrative partnerships.
Kimberly Ha is an award-winning biopharmaceutical industry journalist and editor. She launched BioPharm Insight's editorial team in 2007. Kimberly began her career as a financial journalist in Hong Kong specializing in healthcare M&A, and previously was the lead sector specialist at Mergermarket, a division of the Financial Times Group. She is a sought-after panelist and moderator at major healthcare investor conferences and events. Kimberly is a member of the Galien Foundation Advisory Board. She has received fellowships from organizations including the National Press Foundation, the UN Foundation for Global Vaccines, and the Association of Health Care Journalists. Kimberly earned her Bachelor’s in Psychology from New York University.
About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.
About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.
Read the full story at http://www.prweb.com/releases/2013/4/prweb10624121.htm.
Copyright©2012 Vocus, Inc.
All rights reserved